IN THE NEWS

*OVER PREVIOUS CLOSE

Torrent Pharmaceuticals

2,400 Becomes fourth most

₹2,241.65 CLOSE ▲ 5.14% UP*

valuable pharma stock:

surpasses Biocon, Cipla



A video of Dipali Goenka, CEO and joint MD of Welspun India, dancing with employees to the remixed version



Russel on Wednesday said it has defaulted on payments of ₹1,187.09 crore till December 31, 2019, According to a regulatory filing, the firm said while its total indebtness, inclusive of long-term

₹1,187.09 has been made by the firm. The disclosure follows Sebi tightening its disclosure norms for reporting loan defaults. or the interest amount to lenders borne by listed firms which continues beyond 30 days of the pre-arranged repayment date has to be made public.

First 5G phone in India likely to be

The first 5G-enabled handset in India to be launched by Chinese smartphone maker, Realme, is likely to cost around ₹50,000, a company official said. Realme is set to become the first brand to unveil 5G ready smartphone in India on February 24, he

Google-backed Dunzo raises ₹78 cr from Alteria Capital

Google-backed delivery and

e-commerce firm Dunzo said it has raised \$11 million (over ₹78 crore) from Alteria Capital. It said Alteria Capital has been a crucial peg in Dunzo's mission to become a profitable local e-commerce company. PEERZADA ABRAR

evaluates CEO Sanjay

Sanjay Jalona is likely to get another term to lead the IT services firm after his tenure is comes to an end in August. Sources said board of the firm is weighing an extension proposal. **DEBASIS MOHAPATRA**

Abbott India MD Ambati Venu calls it quits (published on February 19), the firm has clarified that while Venu has resigned as MD of Abbott India, he will continue as its director, and will also take over as vice-president of Abbott's pharmaceutical business in India, which includes the listed Abbott India and the unlisted business, from March 1.

EY Entrepreneur of the Year

tive officer (CEO), Nykaa E-Retail (Start-up); Arun Bharat chairman, (Manufacturing); Sridhar Vembu, founder & CEO, Zoho Corp (Services); Yashish Dahiya, CEO and co-founder, PolicyBazaar Services); Kuldip Singh Gurbachan Singh Dhingra, vice-chairman, Berger Paints (Consumer Products and Retail): Arvind Lal, chairman and managing director, and Om Manchanda, CEO, Dr Lal PathLabs (Life Sciences and Healthcare); KBS Anand, Winners in other cate- managing director and CEO, Asian Paints (Entrepreneurial CEO): and Ravi Raheia and Neel Raheja, group presidents, K Raheja Corp (Energy, Real Estate and

▶ Hindustan Unilever



start-up Unacademy.

The round, which was led

by General Atlantic, was also

participated by Sequoia India,

Nexus Venture Partners,

Steadview Capital and Blume

Ventures. Flipkart's Chief

Executive Officer Kalyan

Krishnamurthy and Udaan co-

founder Suieet Kumar also

took part in the round, which,

according to sources, valued

the company between \$400

In June last year, Facebook

had invested an undisclosed

amount in social commerce

platform Meesho, a start-up

that connects resellers with

customers through channels

such as WhatsApp. "Facebook

is an ally for India's economic

million and \$500 million.

2,320 Analysts believe resilient performance ₹2,293.50 CLOSE



Vodafone Idea

_5.5 Top gainer among





of Muqabla went viral on Wednesday

IN BRIEF

payments of ₹1,187 crore



According to law, any default in repayment of either the principal **AVISHEK RAKSHIT**

priced at ₹50,000 Jalona's extension

L&T Infotech's CEO & MD

In response to a report,

Kiran Mazumdar-Shaw is

SUDIPTO DEY

Mazumdar-Shaw, Kiran chairperson and managing director of Biocon, was named the EY Entrepreneur of the Year (EoY) 2019. She will represent India at the EY World Entrepreneur of the Dhingra, chairman, and Year Award in Monte Carlo, Monaco, in June this year.

The 21st edition of the EoY awards in India also felicitated industrialist Adi Godrej, chairman of Godrej Group Lifetime Achievement Award.

gories included Tuhin Parikh, senior managing director-real estate, Blackstone India (Transformational Impact Person of the Year); Falguni Nayar, founder & chief execu-

Mumbai, 19 February

vear 2020-21.

cycles, they said.

Suzuki Motorcycle India, the two-

wheeler arm of Suzuki Motor

Company, is eyeing double-digit

growth in sales during the financial

financial year with a 7.5 per cent

increase in sales over last year, said

ume ramp up of newly introduced

BS-VI compliant scooter models

Access Gixxer series of motorcycles

Though on a low base, it comes

at a time when rest of the two-

in sales. They do not expect volumes

the company's top officials.

It expects to end the ongoing

The growth will come from vol-

such as the Burgman Street and umes since the last three years.

(Financial Infrastructure).



earnings growth to drive

▶ Shree Cement

__24,900 Inclusion in Nifty50 24,552.20 index with effect from March 27

active API prices 155 ₹ 187.85 CLOSE

FirstCry's holding entity Amitava Saha, FirstCry has

CEO'S DANCE VIDEO GOES VIRAL



McLeod Russel defaults on



L&T Infotech board

Clarification

filings from this facility.

NEW ARENA Unacademy also provided exits to some of its earlier investors,

Funds raised by edtech

companies ir	1 Feb 20)20
Byju's	200	
Unacademy	110	
Vedantu	24	(Figur
Classplus	2.5	in\$m
growth and	social	develo

ment, and we are excited about India and it's rapidly rising internet ecosystem. With this investment in Unacademy, we are reinforcing our commitment to the Indian start-up ecosystem as well as investing in a firm that is transforming learning in India," said Ajit Mohan, vice-president and MD, Facebook India.

With the fresh funding,

which backed it in early stages. The company had so far raised \$88.5 million in six rounds.

Founded in 2015, the Bengaluru-based start-up provides online lessons and specialised courses to crack various competitive examinations such as UPSC, CAT and JEE. "Our goal from day one has

been to democratise education and make quality education accessible to everyone. We do that by bringing the best educators and content on our platform and ensuring it is accessible to everyone across the country," said Gaurav Munjal,

ON THE RISE

Aurobindo Pharma

113.31 $^{\perp}$

75.42

Feb 1,'19 Feb 19,'20

SoftBanktoinvest\$400mninFirstCry

allotted 73.1 million series E

shares at a price of ₹386 each

DEBASIS MOHAPATRA

Bengaluru, 19 February

Baby and mother care products retailer FirstCry has secured around \$400 million (₹2,824.23 crore) SoftBank Vision Fund as part of its Series E funding. While the Japan-based pri-

vate equity fund has infused \$296 million (₹2,120.5 crore) upfront, it has committed another \$100 million (₹703.71 crore) in the second tranche.

According to financial data accessed by business intelligence platform Tofler, Supam Maheshwari and current finacial year.

to SVF Frog, a Cayman Islands-registered entity of from SoftBank as part of the deal. Though how much stake Softbank will hold post this round of funding is not given by the company, media reports had earlier suggested

that SoftBank was looking at

around 40 per cent holding in

the company in lieu of \$400

million investment. Founded in 2010 by

BrainBees Solutions has emerged as the leader in the sunrise baby and mother care sector segment, prompting rising interest of global inves-The funds raised from Softbank are expected to be

used by FirstCry to expand both its offline and online presence as well as to strengthen its technology platform.

The company posted a revenue of ₹535 crore in FY19. which it expects to grow to around ₹2,000 crore in the

Swiggy raises \$113 mn in Series I funding

Food delivery platform Swiggy on Wednesday said it raised \$113 million as part of Series I funding round. The latest round was led by existing investor Prosus NV (earlier called Naspers) and included participation from Wellington Meituan-Dianping and Management Company.

Having grown beyond food delivery, Swiggy aims to use the funds to further execute on our vision while building a susdevelop its new lines of business, addressing tainable path to profitability." PEERZADA ABRAR

visible gaps in the market. The company will continue to invest in new growth areas (Stores, Go and SuprDaily).

"We have created multiple growth avenues for our partners while continuing to invest in new lines of business," said Sriharsha Majety chief executive officer of Swiggy.

"We are laser-focused on continuing to

Aurobindo soars 20% on relief from US regulator

Unit IV, accounting for a third of products pending FDA approvals, gets nod

New Delhi, 19 February

urobindo Pharma got A huge relief with its Unit IV, an injectables plant located in Hyderabad, receiving an establishment inspection report (EIR) from the US Food and Drug Administration (FDA). Investors, too, celebrated, with the company's share price surging 20.4 per cent on Wednesday, leading to an increase of ₹5,980 crore in its market value to ₹35,288 crore on the BSE.

An EIR with voluntary action indicated status means the FDA is not likely to take any action, which could otherwise have hampered drug supplies to the US from this facility. The Street was surprised as analysts were factoring in a much adverse USFDA action on Unit IV.

The facility remains important as it contributes more than 10 per cent to Aurobindo's overall sales and about 20 per cent of the US sales (a majority of injectables supplied to the US market). Further, there were about 46 pending new drug applications (about 30 per cent of 154 pending; see chart) and 50-60 per cent of pending injectable

Since injectables are complex-to-manufacture limitedcompetition products, the company also garners higher margins. Hence, any negative regulatory outcome would have impacted the company's earnings by about a fifth and also delayed new product approvals and future growth.



BREAKTHROUGH

Unit IV accounts for most pending drug approvals Unit-wise ANDA filings as on December 31, 2019

Site	Details	Approvals under rev	riew
Unit III	Oral formulatio	ns	2
Unit IV	Injectables & o	pthalmics	46
Unit VIB	Cephalosporins	oral	1
Unit VII (SEZ)	Oral formulatio	ns	18
UnitX	Oral formulatio	ns	42
Unit XII	Penicillin oral 8	k injectables	-
Aurilife & Aurolife II	Orals & topicals		11
AuroNext	Penem injectal	oles	-
Eugla	Oral & injectable	le formulations	20
APL Healthcare	Oral formulatio	ns	12
Total			154
		Source: Co	mpany

Analysts at Securities now expect the company's US injectables segment to grow 22 per cent annually over 2018-19 and 2021-22, driving overall revenue by 17.1 per cent annually during the period.

The firm has been reporting strong growth in key geographies. The US, which is

ICICI about half of Aurobindo's sales, had grown by 22 per cent year-on-year (YoY) in the December quarter (23.5 per cent in constant currency terms), driven by injectables, orals, and other drugs. The injectables business reported robust growth of 24 per cent to \$76 million, contributing about a fifth to US revenue.

tributing a fourth to overall sales, grew 14.2 per cent YoY (19 per cent in euro terms) in the December quarter. Analysts remain positive on

European revenue, con-

Aurobindo's future prospects, including the US, despite a higher base. Low product concentration (less dependence on a particular product) also provides comfort on the company, which continues to grow on the back of a strong pipeline and the launch of new drugs.

acquisition The Sandoz's portfolio in the US further diversify Aurobindo's dermatology segment. The acquisition though has been slightly delayed and is now expected to close by the end of 2019-20 (FY20). It is looked as a major trigger for Aurobindo and is to further boost its earnings

Analysts at Motilal Oswal Services had Financial already raised their earnings estimates for FY20 and 2020-21 to factor in better traction in existing products in the US and the European Union and their price-to-earnings (P/E) multiple to 9x (from 8x earlier) to include the synergy benefits from Sandoz acquisition and improving prospects in Europe. After the clearance of Unit IV. analysts at ICICI Securities have increased their P/E multiple for the stock to 10x.

Meanwhile, after the resolution of regulatory issues of Unit IV, the firm still requires to resolve USFDA issues related to Unit XI (now under warning letter) and Units VII, I, and IX, which have official action indicated (OAI) status.

DoT still working on final calculation of pending AGR dues PRESS TRUST OF INDIA **Vodafone Idea**

New Delhi, 19 February

Department Telecommunications (DoT) is still working on final adjusted gross revenue dues that service providers have to pay as it has detected variation in accounting practices adopted by different circle offices, according to official sources.

The licence finance wing of the DoT on February 3 issued a letter with guidelines to all controller generals of communication accounts to reconcile adjusted gross revenue (AGR) dues and asked them to give 15 days time to operators for the submission of appeals and documents related to deductions they make in the final payment, sources said. The letter was a follow up

o a previous note sent by the licence finance wing on December 4 and a follow-up on December 13 to the circles for re-verification of debit voucher reports (DVR). "The department has

been facing a challenge in carrying out the revised assessments due to various issues related to DVRs. Telecom operators, including Airtel and Vodafone Idea, have challenged many DVRs. not adopted uniform practice

in accounting. The DoT has

asked them to re-verify DVRs

at the earliest in the light of Supreme Court judgement," an official source said. Telecom operators have towards usage charges and roaming

have

deductions

Sales have been growing steadily

1.99 2.48

Market share (%)

IN TOP GEAR

■ Volumes (units)

FY17

shares surge over 38%

Vodafone Idea's shares on Wednesday gained 38 per cent amid reports that the government is unlikely to invoke the firm's bank guarantees as of now. On BSE, the stock

gained as much as 48.18 per cent to ₹4.49 intraday. It closed 38.28 per cent higher at ₹4.19. On the National Stock Exchange (NSE), the scrip

rose 48.33 per cent to touch a high of ₹4.45. Later, after shedding some gains, it settled 40 per cent up at ₹4.20. The stock has ended the day in green after

consecutive sessions. The NSE saw an exchange of more than 100 crore shares of Vodafone Idea, and over 14 crore units were traded

on the BSF.

claimed by telecom operators on a paid basis while on an accrual basis on the other.

"DoT noticed that many "Also, circle offices have controllers of communication accounts have been cherry picking the figures claimed by telecom operators in their final DVRs. In some cases, DoT guidelines regarding deduction verification issued in 2014, 2015 and 2016 been submitting two separate have not been followed. audited details of deduction There have been cases where interconnection one CCA has allowed one kind of deduction and fee to the DoT. In one set, another has disallowed," the source said.

Suzuki Motorcycle on road to beat slump, hopes to log double-digit growth

Expects to end FY21 with a 7.5% increase in sales on volume ramp-up of BS-VI compliant models **SHALLY SETH MOHILE**

> Unlike most peers at rival twowheeler companies, Koichi Hirao, managing director at Suzuki Motorcycle India, is confident of the road ahead. And for a reason – after years of struggle in a highly-competitive market, dominated by four companies, things have started looking up for Suzuki. Amid one of the most prolonged slowdowns facing the automobile market in India, Suzuki Motorcycle has seen a con-

that is, before the festive season.

Its share in the segment has as well as greater focus on motorinched up to 3.88 per cent in the first 10 months of financial year 2019-20 from 1.90 per cent in FY16. Volumes in the same period have grown to wheeler makers are staring at a fall

sistent gain in market share and vol-

592,646 units from 313,000 units. Hirao attributes the success to

to pick up for another three quarters, the change in tack in terms of products and network strategy. "We attribute this success to the

connect with buyers we have managed to establish," Hirao told Business Standard on the sidelines of the Auto Expo in Greater Noida earlier this month.

His company was the lone twowheeler maker in the mass segment to participate in the show. The slowdown pains forced others, including market leader Hero MotoCorp, to give the show a miss. A strategic call three years ago to vacate the mass commuter motorcycle market (110 cc) and instead focus on the so-called performance segment (150 cc and above) also helped.

"We realised, globally, we are known for performance products. Hence, we will rather focus on that scooter.



and moved out of the commuter seg-An exit from the commuter segment," said Hirao. The turnaround ment meant the company no longer efforts gathered momentum after needed to have a very strong presence in rural and semi-urban marlaunch of the new generation Access

Two-wheeler domestic sales; * Ten months of FY20

strategy and expanded it in areas which mattered, said Devashish Handa, vice-president, sales and marketing, at the firm. The network kets. Hence, it reworked network has grown to 520 now from 300 in

FY18

now come from the urban markets, he said. Meanwhile, Suzuki is looking to reduce dependence on scooters and sees the ratio between scooters to 3.05 3.88 motorcycles settle at 80:20 in the

2016 and close to 70 per cent of sales

Though Suzuki Motorcycle has a long distance to cover to catch up with bigger rivals, including TVS and Bajaj, the consistent increase in volumes has given it a lot of confi-

The overall two-wheeler market,

next one year from the current 90:10.

in the first 10 months of the current financial year, has contracted to 1.5 million units from 1.8 million units in the corresponding period. "We were not on the growth path

earlier. We have seen double-digit growth in the last three years. Most of the growth in the months ahead will come from the Gixxer series -150 and 250," said Handa,